Brand Manufacturer Lawsuits Over Compounded GLP-1 Drugs

Brand-name GLP-1 manufacturers are no longer waiting on the FDA. Several now file private lawsuits directly against compounding pharmacies, telehealth sellers, and the clinics that dispense through them, built on false advertising and trademark theories rather than agency enforcement. A cease-and-desist letter is often the first sign a compounder receives that a manufacturer views its marketing, not only its compounding practice, as the legal problem. Private litigation runs on a different track than an FDA warning letter, with its own discovery, injunction, and damages exposure, and how a pharmacy responds in the first days after that letter arrives can shape everything that follows.

Private Litigation Versus FDA Action

FDA warning letters address labeling and promotional claims under the FDCA and can lead to an injunction the Department of Justice pursues on the agency's behalf. A manufacturer's private lawsuit is a separate track, brought by the manufacturer's own counsel under the Lanham Act and state law, with civil discovery, depositions, and document production that a warning letter never triggers. A private plaintiff can seek a preliminary injunction faster than an agency can act, and it can recover monetary damages and attorney's fees that an FDA enforcement action cannot. That FDA track already reaches anticipatory compounding limits, API sourcing documentation, and beyond-use dating; the private-litigation track is separate, and it reaches marketing claims instead.

The False Advertising and Trademark Theories

A Lanham Act false advertising claim requires a false or misleading statement in commercial advertising, actual or likely consumer deception, a material effect on purchasing decisions, an effect on interstate commerce, and likely injury to the manufacturer as a competitor. The claim most often targets equivalence language: marketing that describes a compounded product as the same as, or a generic version of, an FDA-approved drug when compounded product is not FDA-approved under 503A/503B. The trademark theory is narrower and does not require a false statement at all. Using a manufacturer's brand name in a domain name, ad copy, or metadata can support infringement or unfair competition on a likelihood-of-confusion theory, even where the compounder never claims equivalence. Truthfully naming the active ingredient is generally protected; implying affiliation, approval, or sponsorship is not.

A brand manufacturer does not need an FDA finding to sue. It needs only a false or misleading claim, a likelihood of confusion, or an unauthorized use of its trademark in the compounder's own marketing.

State Consumer Protection Claims Run Alongside

Manufacturers frequently pair a federal Lanham Act count with a claim under the state unfair and deceptive acts and practices (UDAP) statute where the compounder or telehealth seller operates, filed in the same complaint. State UDAP claims can reach conduct the Lanham Act does not, since a private consumer, not only a competitor, may have standing to sue in some states, and remedies can include statutory penalties or treble damages that federal law does not provide. A state attorney general can also open a separate inquiry into the same marketing claims, on a timeline independent of any private suit.

The Cease-and-Desist Letter: First Moves on Receipt

A cease-and-desist letter is a demand, not a filed complaint, and it should never be answered directly by the person who received it. The first move is a litigation hold: preserve the website as it existed on the date of the letter, along with ad copy, email campaigns, and any vendor or affiliate marketing the pharmacy did not author itself. The second is a compliance check on the parallel exposure a manufacturer's counsel may already be watching, confirming that cGMP documentation, beyond-use date logs, and USP 797/800 sterile compounding records are current. Changing marketing language before counsel reviews the letter can read as an admission; the response belongs to counsel, not to the pharmacy's marketing team.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and telehealth sellers promptly retain experienced healthcare defense counsel upon receiving a cease-and-desist letter, a demand letter, or a filed complaint from a brand-name manufacturer. Early legal intervention can protect the business's rights, shape the record before litigation begins, avoid inadvertent admissions in a rushed public response, and preserve defenses such as nominative fair use before a manufacturer's deadline passes. Delaying legal representation can significantly affect the outcome of the matter and expose the business to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance has represented 2,500+ clients over 25+ years, including compounding pharmacies and telehealth healthcare businesses facing both regulatory scrutiny and private litigation over GLP-1 receptor agonist marketing. Our compounding pharmacy attorneys evaluate cease-and-desist letters, respond to false advertising and trademark demands, and defend compounders once a manufacturer has filed suit. Contact Health Law Alliance for a free, confidential consultation.